Levodopa/Carbidopa/Entacapon Neuraxpharm

Levodopa, carbidopa, entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Neuraxpharm, is a combination anti‑Parkinson agent presented as an oral tablet for oral use. It is indicated for the treatment of Parkinson's disease in adults. GNH USA supplies Levodopa/Carbidopa/Entacapone Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor fluctuation syndromes. - Parkinson's disease (early stage): improves motor symptoms when used with other dopaminergic agents. - Parkinson's disease (advanced with motor fluctuations): reduces OFF periods and increases ON time. - Parkinson's disease (adjunct therapy): enhances overall dopaminergic response and stabilises symptom control.

Adverse reactions may occur with any dose of Levodopa/Carbidopa/Entacapone.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually self‑limiting. - Insomnia: difficulty falling or staying asleep. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary movements that may be disabling. - Hallucinations: visual or auditory disturbances, especially in older patients. - Severe hypotension: marked blood pressure fall requiring medical attention. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Anaphylaxis: acute allergic response with rash, swelling, or breathing difficulty.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution and monitor liver enzymes. - Cardiovascular disease: monitor blood pressure and heart rate regularly. - Psychiatric history: watch for emergence of hallucinations or confusion. - Concomitant MAO‑B inhibitors: avoid combination to prevent hypertensive events. - Store at room temperature: keep in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapone may interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk hypertensive crisis. - Antipsychotics (e.g., haloperidol): reduce dopaminergic efficacy. - Iron or calcium supplements: decrease levodopa absorption.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (e.g., selegiline): may increase levodopa levels. - Antihypertensive agents: may enhance orthostatic hypotension. - High‑protein meals: may reduce drug bioavailability.